Infection with Bordetella pertussis continues to result in widespread
morbidity and mortality. Although whole cell pertussis vaccines are ef
fective in controlling pertussis, concerns relating to adverse effects
following vaccination have led to the development of a new generation
of pertussis vaccines. Acellular pertussis vaccines have decreased en
dotoxin content and are less reactogenic than whole cell vaccines. The
composition of acellular pertussis vaccines varies, resulting in diff
ering immunogenicity. Recent studies have demonstrated that these vacc
ines, in general, have an efficacy similar to that of whole cell vacci
nes. The development of acellular pertussis vaccines is an advance tha
t should result in less discomfort from vaccination and the potential
for increased vaccine usage, resulting in the possible elimination of
this disease.